Recent Episodes
Watch recent episodes on
PTV News Review
Scroll Left
Scroll Right
Oxford BioMedica: Vector Value: An Interview with Nick Woolf, SVP Corporate Strategy




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Oxford BioMedica: Vector Value: An Interview with Nick Woolf, SVP Corporate Strategy
Released on: May 01, 2007. © PharmaVentures Ltd
Visitors: You are watching a 5 minute preview.
Get more information and subscribe now
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Fintan Walton talks to Nick Woolf, Senior Vice President, Corporate Strategy, Oxford BioMedica, about the company’s ongoing success as it moves toward its ultimate goal of becoming a fully integrated specialty pharmaceutical company.
  • Summary
  • Transcript
  • Participants
  • Company
Fintan Walton talks to Nick Woolf, Senior Vice President, Corporate Strategy, Oxford BioMedica, about the company’s ongoing success as it moves toward its ultimate goal of becoming a fully integrated specialty pharmaceutical company. They review the company’s history and the finances that have been raised since its successful public listing on AIM in 1996. Together, they discuss the challenges of operating within the gene therapy space, and how Oxford BioMedica has leveraged value from its viral vector technology through deal making. Nick also talks about Oxford BioMedica’s recent acquisition of Oxxon Therapeutics, and the landmark deal the company has signed with global giant sanofi-aventis to complete the development of its lead product, the cancer vaccine TroVax®.
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Nick Woolf was appointed to the board of Oxford BioMedica in March 2005, having joined the company in 2002. He has more than eight years experience as a top-rated biotechnology and pharmaceutical analyst and has been involved in all aspects of company financing, ranging from initial public offerings to major corporate deals. Before joining Oxford BioMedica, he served as Director and Head of European biotechnology research at ABN AMRO, where he was responsible for developing its industry coverage. Before that, he was Vice President and Senior Analyst at Robertson Stephens. He was previously at both Nomura and SBC Warburg. Nick is a chartered certified accountant and holds a degree in chemistry from the University of Oxford.
Oxford BioMedica